Facts of Trasmab (trastuzumab)
Product: Trasmab (Trastuzumab Lyophilized Powder for Concentrate for Solution for infusion)
Initial U.S. Approval: 1998
1. For Injection: 150 mg lyophilized powder in a single-dose vial for reconstitution
2. For Injection: 440 mg lyophilized powder in a multiple-dose vial for reconstitution.
Company: Aureate Healthcare
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Trasmab (trastuzumab)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Trasmab (trastuzumab) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
What Trasmab is ?
Trasmab™ (trastuzumab) is a recombinant humanized monoclonal IgG1 antibody (containing 1328 amino acids) produced in Chinese Hamster Ovary (CHO) cell line. It is directed against an antigen called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When trastuzumab binds to HER2 it stops the growth of such cells leading to cell death.
What Trastuzumab is ?
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.
Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. Other severe side effects include heart failure, allergic reactions, and lung disease. Use during pregnancy may harm the baby. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication.
Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the World Health Organization's List of Essential Medicines. A biosimilar was approved in the European Union in November 2017, and in the United States in December 2018.